This is a guideline for reporting serious adverse events of medicines.
This manual provides step-by-step instructions for reporting serious adverse events (SAEs) on the SUGAM portal, the Central Drugs Standard Control Organization's online system for clinical trial management in India. It defines SAE criteria, outlines reporting timeframes (24 hours, 14 days, 30 days), identifies responsible parties (investigators, sponsors, ethics committees), and details the process flow from site investigator registration through SAE submission.
The document covers both online reporting via SUGAM and offline reporting for clinical trials not registered on the portal. It includes procedures for adding and mapping site investigators, initiating clinical trials, submitting various SAE report types, and using the E-Vartalaap communication module for follow-up reports. Screenshots and form illustrations guide users through each portal screen.
| Version | 1.0 |
|---|---|
| Issuing Organization | Central Drugs Standard Control Organization (CDSCO) |
| Developed By | Centre for Development of Advanced Computing (CDAC) |
| Portal | SUGAM |
| Reporting Timeframes | 24 hours, 14 days, 30 days |
| Applicable Region | India |
An SAE is any adverse drug event resulting in death, life-threatening condition, inpatient hospitalization or prolongation of hospitalization (>24 hours), persistent or significant incapacity, congenital anomaly/birth defect, or an important medical event requiring intervention to prevent serious outcomes.
Investigators must report SAEs to CDSCO, sponsor, and ethics committee within 24 hours, and submit due analysis within 14 days. Sponsors must report to CDSCO, head of institution, and ethics committee within 14 days. Ethics committees must forward their report within 30 days of receiving the investigator's report.
Site Principal Investigators who confirm SAEs occurred in their trial must report to CDSCO, their trial sponsor, and ethics committees. Sponsors and ethics committees also have reporting obligations through the portal.